OX40 and OX40L Interaction in Cancer

Author(s): Xinjie Lu*

Journal Name: Current Medicinal Chemistry

Volume 28 , Issue 28 , 2021


  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: OX40 (CD134) and its binding partner, OX40L (CD252), are expressed on activated CD4, CD8 T-cells, and several other lymphoid and non-lymphoid cells. OX40L belongs to a TNF family member, a 34 kDa type II transmembrane protein. The crystallized complex of human OX40 and OX40L is a trimeric contableuration of one OX40L (trimer) and three OX40 monomers. OX40 and OX40L regulate cytokine production from T-cells, antigen-presenting cells, and natural killer (NK) cells, and modulate cytokine receptor signaling.

Methods: In this review, an updated overview of the structural features of OX40/OX40L and their interactions with cancer are provided.

Results: Recent studies have shown that stimulation of OX40 is useful for therapeutic immunization strategies for cancer. OX40 serves as a secondary costimulatory immune checkpoint molecule; the binding of OX40 to its ligand enhances the augmentation, survival, memory formation, effector function, and recall responses of both CD4+ and CD8+ T-cells.

Conclusion: This review highlights that OX40-OX40L interactions play crucial roles in both CD4+ and CD8+ T-cells. Signals through OX40 can abolish the suppressive activity of Tregs, prevent the induction of Tregs from effector T-cells, reduce Foxp3 expression, and induce the proliferation of memory and effector T lymphocytes. Additionally, when transferred into tumor-bearing recipients, they generate proliferation capability and successfully eliminate the established tumor.

Keywords: OX40, OX40 ligand, cancer, metalloprotease, natural killer cells, T-cells.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 28
ISSUE: 28
Year: 2021
Published on: 29 December, 2020
Page: [5659 - 5673]
Pages: 15
DOI: 10.2174/0929867328666201229123151
Price: $65

Article Metrics

PDF: 305